A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

NCT00160667 PHASE2 COMPLETED Results posted

Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.

Details

Lead sponsor	UCB Pharma
Phase	PHASE2
Status	COMPLETED
Enrolment	152
Start date	Mon Oct 11 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 05 2006 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neuralgia, Postherpetic

Interventions

• Placebo
• Brivaracetam

Countries

France, Slovakia, Belgium, Serbia, United Kingdom, Germany, Poland, Bulgaria, Spain, Czechia